Recent advances in the development of selective androgen receptor modulators

Bibliography

• Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987;8:1-28
   PubMed Web of Science ®Google Scholar
• Bagatell CJ, Bremner WJ. Androgen in men – uses and abuses. N Engl J Med 1996;334:707-14
   PubMed Web of Science ®Google Scholar
• Beers MH, Berkow R. Male hypogonadism. In: The Merck Manual of Diagnosis and Therapy, 17th edition. Merck: Whitehouse Station, NJ, 2003
   Google Scholar
• Liverman CD, Blazer DG. Testosterone and aging: clinical research directions. Institute of Medicine report Natl Acad Press: Washington, D.C; 2004
   Google Scholar
• Diamond TH. Pharmacotherapy of osteoporosis in men. Exp Opin Pharmacother 2005;6:45-58
   PubMed Web of Science ®Google Scholar
• Vanderschueren D, Vandenput L, Boonen S, et al. Androgen and bone. Endocr Rev 2004;25:389-425
   PubMed Web of Science ®Google Scholar
• Cameron DR, Braunstein GD. Androgen replacement therapy in women. Fertil steril 2004;82:273-89
   PubMed Web of Science ®Google Scholar
• Buster JE, Kingsberg SA, Aguirre O, et al. Low-dose estradiol spray to treat vasomotoe symptoms: a randomized controlled trial. Obstet Gynecol 2005;105:944-52
   PubMed Web of Science ®Google Scholar
• Fang H, Tong W, Branham WS, et al. Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol 2003;16:1338-58
   PubMed Web of Science ®Google Scholar
• Burger A, Abraham DJ. Burger's medicinal chemistry and drug discovery, Wiley, 2003
   Google Scholar
• Dalton JT, Mukherjee A, Zhu Z, et al. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998;244:1-4
   PubMed Web of Science ®Google Scholar
• Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 1995;45:745-52
   PubMed Web of Science ®Google Scholar
• Zhi L, Martinborough E. Selective androgen receptor modulators (SARMs). Annu Rep Med Chem 2001;36:169-80
   Web of Science ®Google Scholar
• Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocr Metab 1999;84:3459-62
   PubMed Web of Science ®Google Scholar
• Allan GF, Sui Z. Therapeutic androgen receptor ligands. Nucl Recept Signal 2003;1:e009
   Google Scholar
• Gao W, Bohl CE, Dalton JT. Chemistry and structural biology of androgen receptor. Chem Rev 2005;105:3352-70
   PubMed Web of Science ®Google Scholar
• Chen J, Kim J, Dalton JT. Discovery and therapeutic promise selective androgen receptor modulators. Mol Interv 2005;5:173-88
   PubMed Web of Science ®Google Scholar
• Buijsman RC, Hermkens PH, van Rijn RD, et al. Non-steroidal steroid receptor modulators. Curr Med Chem 2005;12:1017-75
   PubMed Web of Science ®Google Scholar
• Segal S, Narayanan R, Dalton JT. Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery. Expert Opin Invest Drugs 2006;15:377-87
   PubMed Web of Science ®Google Scholar
• Cadilla R, Turnbull P. Selective androgen receptor modulators in drug discovery: medicinal chemistry and therapeutic potential. Curr Top Med Chem 2006;6:245-70
   PubMed Web of Science ®Google Scholar
• Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007;12:241-8
   PubMed Web of Science ®Google Scholar
• Narayanan R, Mohler ML, Bohl CE, et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal 2008;6:e010
   PubMedGoogle Scholar
• Chengalvala M, Oh T, Roy AK. Selective androgen receptor modulators. Expert Opin Ther Patents 2003;13:59-66
   Web of Science ®Google Scholar
• Mohler ML, Nair VA, Hwang DJ, et al. Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidates. Expert Opin Ther Patents 2005;15:1565-85
   Web of Science ®Google Scholar
• Bossola M, Pacelli F, Doglietto GB. Cancer cachexia: drugs in the patent literature. Expert Opin Ther Patents 2008;18:739-57
   Web of Science ®Google Scholar
• Yin D, Gao W, Kearbey JD, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003;304:1334-40
   PubMed Web of Science ®Google Scholar
• University of Tennessee Research Foundation. Preparation of arylamides as selective androgen receptor modulators. WO2002016310; 2002
   Google Scholar
• University of Tennessee Research Foundation. Treating muscle wasting with selective androgen receptor modulators. WO2003049675; 2003
   Google Scholar
• University of Tennessee Research Foundation. Treating benign prostate hyperplasia and hair loss with SARMs. WO2003065992; 2003
   Google Scholar
• University of Tennessee Research Foundation. Preparation of 2-hydroxy-2-methyl-3-(phenylamino)propionamides as selective androgen receptor modulators for treatment of prostate cancer. WO2003106401; 2003
   Google Scholar
• University of Tennessee Research Foundation. Treating obesity with selective androgen receptor modulators. WO2004034978; 2004
   Google Scholar
• University of Tennessee Research Foundation. Treating androgen decline in aging male (ADAM)-associated conditions with selective androgen receptor modulators (SARMs). WO2004035739; 2004
   Google Scholar
• University of Tennessee Research Foundation. Treating bone-related disorders with selective androgen receptor modulators. WO2005037201; 2005
   Google Scholar
• University of Tennessee Research Foundation. Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators. WO2007027582; 2007
   Google Scholar
• University of Tennessee Research Foundation. Selective androgen receptor modulators, substituted acylanilides, and methods of use thereof in treating of diseases including muscle wasting disease and bone-related diseases. WO2008024456; 2008
   Google Scholar
• University of Tennessee Research Foundation. Phenoxypropionic acid benzamides and related compounds as selective androgen receptor modulators (SARMs) for treating diabetes, diseases associated with diabetes, and other disorders. WO2008127717; 2008
   Google Scholar
• Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5? -reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocr 2004;145:5420-8
   PubMed Web of Science ®Google Scholar
• Kearbey JD, Wu D, Gao W, et al. Pharmacokinetics of S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl) propionamide in rats, a non-steroidal selective androgen receptor modulator. Xenobiotica 2004;34:273-80
   PubMed Web of Science ®Google Scholar
• Wu D, Gao W, Kearbey JD, et al. AAPS J. (special issues). AAPS Pharm Sci 2003;5(4): abstract W5267
   Google Scholar
• Gao W, Wu D, Chung K, et al. AAPS J. (special issues). AAPS Pharm Sci 2003;5(4): abstract T3337
   Google Scholar
• Perera MA, Yin D, Wu D, et al. In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs. Drug Metab Dispos 2006;34:1713-21
   PubMed Web of Science ®Google Scholar
• Chen J, Hwang DJ, Bohl CE, et al. A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther 2005;312:546-53
   PubMed Web of Science ®Google Scholar
• Jones A, Chen J, Hwang DJ, et al. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocr 2009;150:385-95
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb, Inc. Synthesis of selective androgen receptor modulators and methods for their identification, design and use. WO2002000617; 2002
   Google Scholar
• Ostrowski J, Kuhns JE, Lupisella JA, et al. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocr 2007;148:4-12
   PubMed Web of Science ®Google Scholar
• Hamann LG, Manfredi MC, Sun C, et al. Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators. Bioorg Med Chem Lett 2007;17:1860-4
   PubMed Web of Science ®Google Scholar
• Sun C, Robl JA, Wang TC, et al. Discovery of potent, orally-active, and muscle-selective androgen receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold. J Med Chem 2006;49:7596-9
   PubMed Web of Science ®Google Scholar
• Li JJ, Sutton JC, Nirschl A, et al. Discovery of potent and muscle selective androgen receptor modulators through scaffold modifications. J Med Chem 2007;50:3015-25
   PubMed Web of Science ®Google Scholar
• Manfredi MC, Bi Y, Nirschl AA, et al. Synthesis and SAR of tetrahydropyrrolo[1,2-b] [1,2,5]thiadiazol-2(3H)-one 1, 1-dioxide analogues as highly potent selective androgen receptor modulators. Bioorg Med Chem Lett 2007;17:4487-90
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson. Preparation of bicyclic fused imidazoles and thiadiazoles as selective androgen receptor modulators. WO2007095423; 2007
   Google Scholar
• Zhang X, Allan GF, Sbriscia T, et al. Synthesis and SAR of novel hydantoin derivatives as selective androgen receptor modulators. Bioorg Med Chem Lett 2006;16:5763-5766
   Google Scholar
• Ligand Pharmaceuticals. Preparation of quinolinones and related bicyclic compounds as androgen and progesterone receptor modulators. WO20010116108; 2001
   Google Scholar
• Ligand Pharmaceuticals. Preparation and formulation of 6-trifluoromethyl-9-pyrido[3,2-g]quinolines as androgen receptor ligands. WO20010116133; 2001
   Google Scholar
• Ligand Pharmaceuticals. Preparation of androgen receptor ligands. WO20010116139; 2001
   Google Scholar
• Ligand Pharmaceuticals. Quinolinones, chromenones, benzothiopyranones, and anilines as androgen receptor modulators, their preparation, pharmaceutical compositions, and use in therapy. WO2007005887; 2007
   Google Scholar
• Ligand Pharmaceuticals. Oxazachrysenedione derivatives as androgen receptor modulators and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2007075884; 2007
   Google Scholar
• Hamann LG, Mani NS, Davis RL, et al. Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J Med Chem 1999;42:210
   PubMed Web of Science ®Google Scholar
• Miner JN, Chang W, Chapman MS, et al. An orally-active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate. Endocr 2007;148:363-73
   PubMed Web of Science ®Google Scholar
• van Oeveren A, Pio BA, Tegley CM, et al. Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones. Bioorg Med Chem Lett 2007;17:1523-6
   PubMed Web of Science ®Google Scholar
• van Oeveren A, Motamedi, M, Mani NS, et al. Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem 2006;49:6143-6
   PubMed Web of Science ®Google Scholar
• Martinborough E, Shen Y, Oeveren A, et al. Substituted 6-(1-pyrrolidine) quinolin-2(1H)-ones as novel selective androgen receptor modulators. J Med Chem 2007;50:5049-52
   PubMed Web of Science ®Google Scholar
• Wang F, Liu XQ, Li H, et al. Structure of the ligand-binding domain (LBD) of human androgen receptor in complex with a selective modulator LGD2226. Acta Crystallograph Sect F Struct Biol Cryst Commun 2006;62:1067-71
   PubMedGoogle Scholar
• Vajda EG, Lopez FJ, Rix P, et al. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator. J Pharmacol Exp Ther 2009;328:663-70
   PubMed Web of Science ®Google Scholar
• 2007 American Society for Bone and Mineral Research (ASBMR) Meeting (unpublished data) cited in ref. 22
   Google Scholar
• Higuchi RI, Arienti KL, Lopez FJ, et al. Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem 2007;50:2486-96
   PubMed Web of Science ®Google Scholar
• Higuchi RI, Thompson AW, Chen JH, et al. Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones. Bioorg Med Chem Lett 2007;17:5442-6
   PubMedGoogle Scholar
• Zhao S, Shen Y, van Oeveren A, et al. Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones. Bioorg Med Chem Lett 2008;18:3431-5
   Google Scholar
• Merck & Co, Inc. Preparation of chromenoazepinones and azepinoquinolinones as androgen receptor modulators. US7196076; 2007
   Google Scholar
• Kaken Pharmaceutical Co Ltd. Preparation of tetrahydroquinoline derivatives as androgen agonists or antagonists. US6777427; 2004
   Google Scholar
• Kaken Pharmaceutical Co Ltd. Preparation of tetrahydroquinoline derivatives as androgen receptor regulators WO2001027086; 2001
   Google Scholar
• Kaken Pharmaceutical Co Ltd. Preparation of novel tetrahydroquinoline derivatives as androgen receptor agonists. WO2004013104; 2004
   Google Scholar
• Kaken Pharmaceutical Co Ltd. Preparation of bicyclic tetrahydroquinoline derivatives as androgen receptor agonists. WO2004000816; 2004
   Google Scholar
• Hanada K, Furuya K, Yamamoto N, et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptormodulator (SARM), in rat models of osteoporosis. Biolog Pharm Bull 2003;26:1563-9
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson. Novel heterocyclic derivatives useful as SARMs. US20060211756; 2006
   Google Scholar
• Zhang X, Li X, Allan GF, et al. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators. J Med Chem 2007;50:3857-69
   PubMed Web of Science ®Google Scholar
• Allan GF, Tannenbaum P, Sbriscia T, et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 2007;32:41-51
   PubMed Web of Science ®Google Scholar
• Johnson & Johnson. Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators. WO2007092727; 2007
   Google Scholar
• Zhang X, Li X, Allan GF, et al. Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgen receptor modulators. Bioorg Med Chem Lett 2007;17:439-43
   Google Scholar
• Zhang X, Allan GF, Tannenbaum P, et al. Pharmacological profile of an imidazolopyrazole derivative: a novel selective androgen receptor modulator. Eur J Pharmacol (Submitted)
   Google Scholar
• Johnson & Johnson. Preparation of benzimidazole derivatives as selective androgen receptor modulators. WO2006039215; 2006
   Google Scholar
• Johnson & Johnson. Preparation of benzimidazole derivatives as selective androgen receptor modulators. WO2006039243; 2006
   Google Scholar
• Johnson & Johnson. Preparation of trifluoroethyl benzimidazoles as selective androgen receptor modulators (SARMs). WO2007087518; 2007
   Google Scholar
• Ng RA, Guan J, Alford VC, et al. Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives. Bioorg Med Chem Lett 2007;17:784-8
   PubMedGoogle Scholar
• Ng RA, Lanter JC, Alford VC, et al. Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-Trifluoroethyl-benzimidazole scaffold. Bioorg Med Chem Lett 2007;17:1784-7
   PubMedGoogle Scholar
• Allan GF, Sbriscia T, Linton O, et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity restores lean body mass in aged orchidectomized male rats. J Steroid Biochem Mol Biol 2008;110:207-13
   PubMed Web of Science ®Google Scholar
• Eli Lilly. Tetrahydrocyclopenta[b]indole compounds as therapeutic selective androgen receptor modulators. WO2008063867; 2008
   Google Scholar
• Johnson & Johnson. Preparation of novel indole derivatives as selective androgen receptor modulators (SARMs). US2005250741; 2005
   Google Scholar
• Johnson & Johnson. Preparation of novel indole derivatives as selective androgen receptor modulators (SARMs). US2005250740; 2005
   Google Scholar
• Johnson & Johnson. Preparation of novel indole derivatives as selective androgen receptor modulators (SARMs) US2005245485; 2005
   Google Scholar
• Lanter JC, Fiordeliso JJ, Alford VC, et al. β -Alkylthio indolyl carbinols: potent nonsteroidal antiandrogens with oral efficacy in a prostate cancer model. Bioorg Med Chem Lett 2007;17:2545-8
   Google Scholar
• Allan GF, Lai MT, Sbriscia T, et al. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. J Steroid Biochem Mol Biol 2007;103:76-83
   PubMed Web of Science ®Google Scholar
• Eli Lilly. Preparation of N-arylpyrrolidine derivatives as selective androgen receptor modulators. WO2006124447; 2006
   Google Scholar
• Pfizer Products, Inc. Preparation of amino-substituted benzonitriles as androgen receptor modulators to treat musculoskeletal frailty. WO2005108351; 2005
   Google Scholar
• GlaxoSmithKline Co. Preparation of substituted anilines as androgen receptor modulators. WO2005000795; 2005
   Google Scholar
• GlaxoSmithKline Co. Preparation of aniline amino acid derivatives as selective androgen receptor modulators. WO2005085185; 2005
   Google Scholar
• GlaxoSmithKline Co. Preparation of substituted anilines as selective androgen receptor modulators. WO2006044707; 2006
   Google Scholar
• University of Tennessee Research Foundation. Substituted arenes and heteroarenes as selective androgen receptor modulators, analogs and derivatives thereof and uses thereof. WO2008011072; 2008
   Google Scholar
• Takeda Pharmaceutical. Preparation of cyclic amine compounds as androgen receptor modulators. WO2008066117; 2008
   Google Scholar
• Acadia Pharmaceutical. Preparation of arylazabicyclooctanols and related compounds as selective androgen receptor modulators. WO2006076317; 2006
   Google Scholar
• Piu F, Gardell LR, Son T, et al. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J Steroid Biochem Mol Biol 2008;109:129-37
   PubMed Web of Science ®Google Scholar
• Merck & Co, Inc. Synthesis and uses of 4-azasteroid derivatives as selective androgen receptor modulators (SARMs). WO2003092588; 2003
   Google Scholar
• Merck & Co, Inc. Preparation of 17-acetamido-4-azasteroid derivatives as tissue selective androgen receptor modulators. WO2005009949; 2005
   Google Scholar
• Merck & Co, Inc. Preparation of 21-heterocyclic-4-azasteroid derivatives as selective androgen receptor modulators. WO2005044988; 2005
   Google Scholar
• Endorecherche, Inc. Preparation of 17?-substituted steroids as systemic antiandrogens and selective androgen receptor modulators. WO2008124922; 2008
   Google Scholar
• Johnson & Johnson. Preparation of novel imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMs). US2006063819; 2006
   Google Scholar
• Johnson & Johnson. Preparation of thiazoline derivatives as selective androgen receptor modulators (SARMs). WO2004113309; 2004
   Google Scholar
• Merck & Co, Inc. N-benzyl-2-phenylbutanamides as tissue-selective androgen receptor modulators, their preparation, pharmaceutical compositions, and use in therapy. US2005277681; 2005
   Google Scholar
• Merck & Co, Inc. N-(4-Oxo-3, 4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators, their preparation, pharmaceutical compositions, and use in therapy. WO2007038444; 2007
   Google Scholar
• Merck & Co, Inc. Preparation of 2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators. WO2008048540; 2008
   Google Scholar
• Merck & Co, Inc. Preparation of carbonylamino-benzimidazoles as selective androgen receptor modulators. WO2004041277; 2004
   Google Scholar
• GlaxoSmithKline Co. Preparation of benzoxazepines as androgen receptor modulators for treating various diseases. WO2008121602; 2008
   Google Scholar
• Han, et al. the 89th Annual Endocrine Society Meeting (June, 2007) cited in ref. 22
   Google Scholar
• As reported on ClinicalTrials.gov (a service of the U.S. National institute of health) cited in ref. 22
   Google Scholar
• Ligand Pharmacuticals. Thiazole derivatives as androgen receptor modulator compounds and their preparation, pharmaceutical compositions and their use in the treatment of diseases. WO2008124000; 2008
   Google Scholar